NTHU
19.2.2020 10:02:05 CET | Business Wire | Press release
A research team led by Professor Hsueh-Shih (Sean) Chen of National Tsing Hua University has recently announced that they have developed a new quantum dot material which is more stable and provides more realistic color. The main limitations of the current quantum dot display materials is that they are unstable and easily damaged, and the team has rectified this by growing “shield” with approximately 1-nanometer at the crystal facets of each quantum dot. The new material has a wide range of applications, including the screens used in televisions, computers, mobile phones, and cameras.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005017/en/
With the support of NTHU, the team has already applied for patents for the new material and has established the HsinLight Inc. to produce it on a commercial scale. It is expected that the first quantum dot screens will begin production in 2020.
Most of the displays currently on the market are liquid crystal displays (LCD), which have a color gradation and saturation and can only display about one third of the colors visible to the human eye, and even the so-called “retinal grade” OLED displays used in such devices as iPhone 11 can only display about half of the colors visible to the human eye. Displays equipped with new QD material (QLED TV) will display nearly 90% of the colors visible to the human eye.
However, there are still a few challenges to be overcome before quantum dot material goes into widespread use. Chen explained that quantum dots are spherical crystals of about three nanometers in size, and are easily damaged by water and oxygeny molecules, which diminishes their luminosity. At present, major manufacturers such as Samsung control this problem by sandwiching the quantum dots in a layer of protective film, but it’s not cost-effective and easily lose the protective function if there is a small pin hole.
Inspired by the shield used by the comic book superhero Captain America in the Avengers series, Chen hit upon the idea of giving each quantum dot its own shields about one nanometer in size, which effectively resists water and oxidation and also increases material stability and the display’s lifespan.
In the past two years several companies have begun selling televisions with quantum dot technology, but due to the fragile nature of quantum materials, they are difficult to mass produce, and the price is relatively high. However, using Chen’s unique shield technology to protect the quantum dots will significantly reduce production costs.
A typical 55-inch quantum dot screen consists of more than 100 million trillion (10 to the 20th power) quantum crystals, and Chen's research team has developed a technique for precisely controlling the size of each quantum dot, so that each quantum crystal differs in size by no more than 0.5 nanometers. Precisely controlling the size of the quantum dots and shields allows them to accurately emit blue, green, yellow, orange, red, infrared, and other colors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom